Current News

Contact | Print version | PDF version | Send article | RSS feed

Probiodrug Obtains Core Patent for Alzheimer Treatment in the U.S.

18 Jun 2008 - Probiodrug AG announced that the United States Patent Office issued to Probiodrug the US patent no. 7,381,537, the first patent covering broad methods of treating Alzheimer's disease using compounds that inhibit mammalian glutaminyl cyclase (QC).
 
"We are very pleased about this patent as QC inhibition is at the core of our new treatment paradigm in Alzheimer's disease", said Hans-Ulrich Demuth, CSO and co-founder of Probiodrug. "This is the first patent covering a method that has the potential to be a frontline therapy for Alzheimer's disease."
 
"Probiodrug has a strong intellectual property program with over 160 patent applications for broad coverage of QC inhibitors, including composition of matter, formulations, and methods of treatment claims," says Matthias Hoffmann, VP Operations and Head of Intellectual Property. "These methods of treatment claims add to two U.S. patents issued to Probiodrug in April and May 2008, which cover the first small molecule inhibitors of glutaminyl cyclase."